The supply of GLP-1 drugs has been increasing, but they’re still expensive for most patients. Here are answers to some ...

Access remains limited to these effective but expensive drugs, even for patients covered by Medicaid, because of stringent prerequisites that must be satisfied before starting the drug.

Health insurance plans are changing how they cover GLP-1 drugs for weight loss to rein in costs, forcing doctors and patients ...

KFF Health News journalists made the rounds on national and local media recently to discuss topical stories. Here’s a ...

Novo Nordisk will sell a less expensive one-month supply of Wegovy for patients who previously took compounded versions of ...

Cigna’s pharmacy benefits unit Evernorth said the deal will bring prices down for employers and their workers.

As of late 2024, only 14 state Medicaid programs cover GLP-1 drugs like Wegovy, Saxenda, or Zepbound for the treatment of obesity. These states are: California, Connecticut, Indiana, Maryland, ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...